Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PPBT Stock Forecast 2025-2026
$2.21
Current Price
$5.84M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PPBT Price Targets
+1,396.6%
To High Target of $33.00
+1,396.6%
To Median Target of $33.00
+1,396.6%
To Low Target of $33.00
PPBT Price Momentum
-10.6%
1 Week Change
-12.0%
1 Month Change
-79.0%
1 Year Change
-53.1%
Year-to-Date Change
-89.3%
From 52W High of $20.60
+10.3%
From 52W Low of $2.00
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Purple Biotech (PPBT) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PPBT and similar high-potential opportunities.
Latest PPBT Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, PPBT has a bullish consensus with a median price target of $33.00 (ranging from $33.00 to $33.00). Currently trading at $2.21, the median forecast implies a 1,396.6% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Emily Bodnar at HC Wainwright & Co., projecting a 1,396.6% upside. Conversely, the most conservative target is provided by Emily Bodnar at HC Wainwright & Co., suggesting a 1,396.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PPBT Analyst Ratings
1
Buy
0
Hold
0
Sell
PPBT Price Target Range
Low
$33.00
Average
$33.00
High
$33.00
Current: $2.21
Latest PPBT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PPBT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $33.00 |
| Sep 20, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $33.00 |
| Aug 19, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $8.00 |
| Jul 11, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $10.00 |
| May 21, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $10.00 |
| Apr 26, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $10.00 |
| Mar 7, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $11.00 |
| Mar 5, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $10.00 |
| Feb 27, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $10.00 |
| Nov 21, 2023 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $10.00 |
| Aug 31, 2023 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $9.00 |
| Aug 30, 2023 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $9.00 |
| Jul 21, 2023 | JonesTrading | Catherine Novack | Buy | Initiates | $8.00 |
| May 17, 2023 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $7.00 |
| May 17, 2023 | Chardan Capital | Matthew Barcus | Buy | Reiterates | $11.00 |
| Feb 9, 2023 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $7.00 |
| Feb 9, 2023 | Chardan Capital | Matthew Barcus | Buy | Reiterates | $11.00 |
| Oct 17, 2022 | HC Wainwright & Co. | Emily Bodnar | Buy | Initiates | $7.00 |
| Sep 8, 2022 | Chardan Capital | Matthew Barcus | Buy | Initiates | $11.00 |
Purple Biotech Ltd. (PPBT) Competitors
The following stocks are similar to Purple Biotech based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Purple Biotech Ltd. (PPBT) Financial Data
Purple Biotech Ltd. has a market capitalization of $5.84M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -21.7%.
Valuation Metrics
Market Cap
$5.84M
Enterprise Value
$1.16B
P/E Ratio
0.0x
PEG Ratio
-1.0x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+0.7%
Current Ratio
2.2x
Debt/Equity
0.6x
ROE
-21.7%
ROA
-16.6%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Purple Biotech Ltd. (PPBT) Business Model
About Purple Biotech Ltd.
What They Do
Develops novel therapies for cancer treatment.
Business Model
The company advances drug candidates through various clinical trial phases, focusing on innovative solutions for unmet medical needs in oncology. It generates revenue by potentially commercializing successful therapies that target fundamental processes in cancer cell metabolism.
Additional Information
Headquartered in Israel, Purple Biotech emphasizes inhibiting energy supply to cancer cells, which can impact multiple cancer types. Its commitment to scientific advancements and exploration of novel therapeutic mechanisms positions it as a key player in the biotechnology sector, contributing significantly to the fight against cancer.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
9
CEO
Mr. Gil Efron CPA, M.A.
Country
Israel
IPO Year
2015
Website
purple-biotech.comPurple Biotech Ltd. (PPBT) Latest News & Analysis
Latest News
Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers
14 days ago
Quick Summary
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) announced new NT219 data will be presented at the AACR 2025 Annual Meeting on April 27-28, 2025, focusing on therapies for tumor immune evasion and drug resistance.
Why It Matters
The presentation of new data on NT219 at a major cancer research conference highlights Purple Biotech's potential advancements, which could significantly impact its market value and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Successful clinical trials for CM24 and NT21 oncology assets show clinical benefits and identify potential biomarkers.
Why It Matters
Successful clinical trials for CM24 and NT21 enhance the prospects for these oncology assets, potentially increasing their market value and attractiveness to investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
NT219 will be assessed alongside pembrolizumab and cetuximab to address tumor resistance in head and neck cancer treatments.
Why It Matters
The evaluation of NT219 with established cancer drugs could indicate potential breakthroughs in treatment efficacy, impacting market valuations and investor sentiment in oncology.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares
5 months ago
Quick Summary
Purple Biotech Ltd. announced a definitive agreement to sell 472,668 American Depositary Shares at $6.00 each in a registered direct offering, closing expected on December 4, 2024.
Why It Matters
Purple Biotech's direct offering of ADSs at $6.00 may dilute existing shares but provides capital for development. Investors should assess potential impacts on share value and company growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
5 months ago
Quick Summary
Purple Biotech Ltd. closed a registered direct offering of 472,668 ADSs at $6.00 each, raising capital to support its development of cancer therapies.
Why It Matters
The direct offering raises capital for Purple Biotech, potentially funding further development of its therapies, which could influence stock performance and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Purple Biotech stock increased by 150.4% after announcing positive efficacy results from a mid-stage study of its combination therapy for pancreatic cancer patients.
Why It Matters
The 150.4% surge in Purple Biotech stock reflects positive investor sentiment and confidence in its cancer treatment's potential, indicating significant future revenue prospects and market interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About PPBT Stock
What is Purple Biotech Ltd.'s (PPBT) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Purple Biotech Ltd. (PPBT) has a median price target of $33.00. The highest price target is $33.00 and the lowest is $33.00.
Is PPBT stock a good investment in 2025?
According to current analyst ratings, PPBT has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.21. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PPBT stock?
Wall Street analysts predict PPBT stock could reach $33.00 in the next 12 months. This represents a 1,396.6% increase from the current price of $2.21. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Purple Biotech Ltd.'s business model?
The company advances drug candidates through various clinical trial phases, focusing on innovative solutions for unmet medical needs in oncology. It generates revenue by potentially commercializing successful therapies that target fundamental processes in cancer cell metabolism.
What is the highest forecasted price for PPBT Purple Biotech Ltd.?
The highest price target for PPBT is $33.00 from Emily Bodnar at HC Wainwright & Co., which represents a 1,396.6% increase from the current price of $2.21.
What is the lowest forecasted price for PPBT Purple Biotech Ltd.?
The lowest price target for PPBT is $33.00 from Emily Bodnar at HC Wainwright & Co., which represents a 1,396.6% increase from the current price of $2.21.
What is the overall PPBT consensus from analysts for Purple Biotech Ltd.?
The overall analyst consensus for PPBT is bullish. Out of 4 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $33.00.
How accurate are PPBT stock price projections?
Stock price projections, including those for Purple Biotech Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 4:45 AM UTC